- Home
- IMUX vs IKNA Comparison
IMUX vs IKNA Comparison
Compare IMUX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- IKNA
- Stock Information
- Founded
- IMUX 2016
- IKNA 2016
- Country
- IMUX United States
- IKNA United States
- Employees
- IMUX N/A
- IKNA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- IKNA Health Care
- Exchange
- IMUX Nasdaq
- IKNA Nasdaq
- Market Cap
- IMUX 67.8M
- IKNA 61.8M
- IPO Year
- IMUX N/A
- IKNA 2021
- Fundamental
- Price
- IMUX $0.70
- IKNA $1.34
- Analyst Decision
- IMUX Strong Buy
- IKNA Strong Buy
- Analyst Count
- IMUX 6
- IKNA 1
- Target Price
- IMUX $11.60
- IKNA $4.00
- AVG Volume (30 Days)
- IMUX 2.6M
- IKNA 79.7K
- Earning Date
- IMUX 08-07-2025
- IKNA 08-07-2025
- Dividend Yield
- IMUX N/A
- IKNA N/A
- EPS Growth
- IMUX N/A
- IKNA N/A
- EPS
- IMUX N/A
- IKNA N/A
- Revenue
- IMUX N/A
- IKNA N/A
- Revenue This Year
- IMUX N/A
- IKNA N/A
- Revenue Next Year
- IMUX N/A
- IKNA N/A
- P/E Ratio
- IMUX N/A
- IKNA N/A
- Revenue Growth
- IMUX N/A
- IKNA N/A
- 52 Week Low
- IMUX $0.56
- IKNA $0.97
- 52 Week High
- IMUX $2.11
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- IMUX 35.71
- IKNA 54.06
- Support Level
- IMUX $0.68
- IKNA $1.31
- Resistance Level
- IMUX $0.75
- IKNA $1.37
- Average True Range (ATR)
- IMUX 0.06
- IKNA 0.05
- MACD
- IMUX -0.00
- IKNA -0.01
- Stochastic Oscillator
- IMUX 10.40
- IKNA 26.85
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.